|CoLucid CoLucid Pharmaceuticals |
|Care Capital|| |
The financing will be used to develop COL-144, a migraine compound, and to advance preclinical pipeline candidates that target neurological and psychiatric disorders.
|Immune Design |
|Alta Partners, The Column Group and Versant Ventures|| |
The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies.
|Limerick BioPharma |
South San Francisco
|Arch Venture Partners, Sevin Rosen Funds and Altitude Funds|| |
Limerick BioPharma will advance its work on the bioavailability of drugs.
CoLucid gets $25M